Novartis's Farydak Enters EU As First-In-Class Myeloma Therapy
This article was originally published in Scrip
Executive Summary
Novartis AG's histone deacetylase (HDAC) inhibitor Farydak (panobinostat; also known as Faridak) has secured approval in Europe for the treatment of multiple myeloma – making it the first drug of this class to reach the European market.
You may also be interested in...
Deal Watch: Celgene Joins Line Of Partners Tapping Exscientia’s AI-Driven Discovery Engine
While the proposed Bristol/Celgene merger nears an April vote, Celgene continues a recent spate of deal-making, paying $25m up front to Exscientia to discover small molecule candidates for cancer and autoimmune disease.
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.